Vor Biopharma Inc. $VOR Stock Position Raised by UBS Group AG

UBS Group AG lifted its stake in shares of Vor Biopharma Inc. (NASDAQ:VOR) by 284.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 292,118 shares of the company’s stock after acquiring an additional 216,209 shares during the quarter. UBS Group AG’s holdings in Vor Biopharma were worth $3,821,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of VOR. China Universal Asset Management Co. Ltd. bought a new stake in shares of Vor Biopharma during the 4th quarter worth $36,000. Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the 2nd quarter worth $66,000. Jane Street Group LLC bought a new stake in shares of Vor Biopharma during the 1st quarter worth $140,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Vor Biopharma during the 3rd quarter worth $230,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Stock Down 4.7%

Shares of Vor Biopharma stock opened at $14.33 on Friday. The business has a fifty day simple moving average of $15.05 and a 200-day simple moving average of $13.83. Vor Biopharma Inc. has a 12 month low of $3.30 and a 12 month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, equities research analysts expect that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. This trade represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 3,002,903 shares of company stock valued at $49,412,176 over the last ninety days. Company insiders own 0.45% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on VOR shares. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Wells Fargo & Company started coverage on Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Wedbush raised their price objective on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $42.25.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).